Hafnium oxide nanoparticles as a promising emergent treatment for head and neck cancer

Multidisciplinary Head & Neck Cancers Symposium, Scottsdale, Arizona, USA · 2018, Le Tourneau C. et al.

Authors

Le Tourneau C.1, Calugaru V.1, Thariat J.O.2, Florescu C.3, Mirabel X.4, Jegoux F.5, Jouffroy T.1, Rodriguez J.1, Hoffmann C.1, Dodger B.6, Moreno Garcia V.7, Dimitriu M.8, Levy L.8, and Calvo E.6
1 – Institut Curie, Paris, France
2 – Centre Antoine-Lacassagne, Nice, France
3 – Centre Francois Baclesse, Caen, France
4 – Centre Oscar Lambret, Lille, France
5 – Centre Hospitalier Universitaire de Rennes, Rennes, FL, France
6 – START Madrid, Madrid, Spain
7 – Hospital Fundacio´n Jimenez Diaz, Madrid, Spain
8 – Nanobiotix, Paris, France

Summary

NBTXR3 administered as a single intratumoral injection and activated by radiotherapy, is currently evaluated in a phase I clinical trial for head and neck cancer [NCT01946867]. At the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale Arizona, preliminary results were presented by prof. C. Le Tourneau.

So far, patients treated in phase I showed good local and systemic tolerance to the product up to the highest dose level and received radiotherapy as planned, confirming a very good local safety profile. Regarding the patients, the durability of response so far is superior to 13 months, with some patients at 16 and 22 months follow-up without recurrence.

NBTXR3 nanoparticles constitute a rising hope for head and neck cancer patients as it could lead to a decrease in the long-term adverse effects of RT and an improvement in quality of life, associated with strong locoregional control.

Read Article

Contact

Pour plus d’informations, contactez notre équipe des affaires médicales à l’adresse medicalaffairs@nanobiotix.com